Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2016-11-02 Earnings Release
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Quarterly financial report / Third quarter financial report
Earnings Release Classification · 98% confidence The document is explicitly titled "MAUNA KEA TECHNOLOGIES REPORTS THIRD QUARTER 2016 SALES" and contains detailed financial tables comparing Q3 2016 results against Q3 2015, as well as nine-month results. This structure is characteristic of an initial announcement of periodic financial results, focusing on key figures like revenue, sales by category, and geography. This aligns perfectly with the definition of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), as it is presented as a press release announcing the results and mentioning a subsequent conference call, fitting the 'initial announcement of quarterly/periodical financial results (key highlights only)' description for ER. Q3 2016
2016-11-02 English
Information financière trimestrielle / Information financière du troisième trimestre
Earnings Release Classification · 98% confidence The document is titled "MAUNA KEA TECHNOLOGIES ANNONCE SON CHIFFRE D'AFFAIRES DU 3ème TRIMESTRE 2016" (Mauna Kea Technologies Announces its Third Quarter 2016 Revenue). It provides detailed financial figures (revenue by segment, geography, and activity) for the third quarter (T3 2016) and the first nine months (9M 2016) of the year, comparing them to the prior year. This content structure is characteristic of an initial announcement of periodic financial results, focusing on key figures and highlights, rather than the comprehensive annual report (10-K) or a detailed management discussion (MDA). The presence of a conference call announcement further supports this being an Earnings Release (ER). It is not a comprehensive Interim Report (IR) as it focuses only on revenue highlights and does not include full balance sheets or cash flow statements typically found in an IR. Q3 2016
2016-11-02 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 99% confidence The document is a press release dated October 19, 2016, announcing positive clinical study results (CONTACT study) for the Cellvizio device presented at a medical conference (UEGW 2016). It details scientific findings, quotes management and doctors, and includes standard forward-looking statements and contact information typical of a corporate announcement. This format strongly suggests an Earnings Release (ER) or a general announcement related to company performance/developments. Since it is announcing specific clinical trial results that impact the company's product value and market position, it functions as an immediate release of key performance/development information, fitting the 'Earnings Release' category better than a general 'Regulatory Filing' (RNS), especially as it is not a formal SEC filing like 10-K or a specific financial report like IR. It is not a transcript (CT), a formal report (AR/IR), or a management discussion (MDA), but rather a news announcement of a significant event/data release. FY 2016
2016-10-19 French
Communicated under the obligation to provide permanent information / Other communications
Environmental & Social Information Classification · 99% confidence The document is a press release dated October 19th, 2016, announcing positive clinical study results (CONTACT study) regarding the efficacy of the Cellvizio platform in diagnosing pancreatic cysts. It details sensitivity and specificity metrics and includes quotes from the CEO and presenting physician. This type of announcement, focusing on clinical trial outcomes and scientific validation, is characteristic of an Investor Presentation (IP) or a general press release detailing scientific progress, rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or a specific financial report (IR, AR). Since it presents detailed data and context intended for investors and the medical community, Investor Presentation (IP) is the most fitting category, as it often includes such scientific updates. It is not an ER (which focuses on financial performance), not an AR/IR (which are comprehensive financial reports), and not an RPA (which only announces the publication of a report). It is a direct communication of scientific/clinical progress.
2016-10-19 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated October 12, 2016, announcing the launch of a clinical study involving the company's product (Cellvizio) and noting that the project is funded by the NIH. It details a business development/research update rather than reporting periodic financial results (ER/IR), providing management commentary (MDA), or announcing a formal shareholder vote (AGM-R/DEF 14A). Since it is an announcement about a specific business development, research progress, or partnership, it does not fit neatly into the core financial reporting categories (10-K, IR, ER). It is best classified as a general announcement or regulatory filing that doesn't fit elsewhere, leaning towards RNS, but given the content is a specific business/research update, it is often categorized under general news releases. However, none of the specific codes perfectly match a 'Research/Business Update Announcement'. Given the options, and since it is a formal announcement of a significant event (launch of a study, funding secured), it is most appropriately categorized as a general Regulatory Filing (RNS) if it doesn't qualify as a specific financial or governance document. It is not a proxy statement (PSI), director dealing (DIRS), or capital change (CAP). It is a press release announcing a significant operational/research milestone.
2016-10-12 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated October 12, 2016, announcing the launch of a new NIH-funded clinical study involving Mauna Kea Technologies' product, Cellvizio. It details the study's purpose, the researchers involved, and provides background information on the disease area and the company. This type of announcement, focusing on a specific operational event (a study launch) rather than periodic financial results (ER, IR, 10-K) or management changes (MANG), is best classified as a general Regulatory Filing or Announcement, as it is a material event disclosure. Since there is no specific category for 'Clinical Trial Announcement' or 'Operational Update,' and it is not a formal regulatory report like a 10-K or IR, the most appropriate fallback category is Regulatory Filings (RNS), as it is a public announcement of a significant business development.
2016-10-12 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.